Redpoint Investment Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $389K | Sell |
3,662
-1,426
| -28% | -$151K | 0.06% | 380 |
|
|
2022
Q2 | $496K | Hold |
5,088
| – | – | 0.06% | 376 |
|
|
2022
Q1 | $477K | Buy |
5,088
+1,391
| +38% | +$130K | 0.05% | 426 |
|
|
2021
Q4 | $315K | Sell |
3,697
-172
| -4% | -$14.7K | 0.03% | 562 |
|
|
2021
Q3 | $371K | Hold |
3,869
| – | – | 0.03% | 526 |
|
|
2021
Q2 | $377K | Hold |
3,869
| – | – | 0.03% | 529 |
|
|
2021
Q1 | $376K | Hold |
3,869
| – | – | 0.03% | 513 |
|
|
2020
Q4 | $371K | Sell |
3,869
-347
| -8% | -$33.3K | 0.04% | 432 |
|
|
2020
Q3 | $405K | Sell |
4,216
-10,444
| -71% | -$1M | 0.04% | 402 |
|
|
2020
Q2 | $1.79M | Buy |
14,660
+7,509
| +105% | +$916K | 0.1% | 237 |
|
|
2020
Q1 | $619K | Buy |
7,151
+5,105
| +250% | +$442K | 0.04% | 391 |
|
|
2019
Q4 | $220K | Buy |
+2,046
| New | +$220K | 0.01% | 580 |
|